COLORADO SPRINGS, Colo.,
Jan. 16, 2015 /PRNewswire/ --
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, announced on January
5th the International release of eight initial products to
be produced, distributed and marketed across the Netherlands, Spain and California, where Cannabis Science is active
and has cannabis production facilities through ownership and usage
agreements.
The products are currently ready for pre-clinical studies,
self-medicating patient ailment usage, marketing release, sales and
distribution. The roll-out will involve Cannabis Science teams in
both Europe and California to work in tandem to share
information, send formulations to be produced in each respective
production facility and share opt-in patient data based on usage
metrics to scale demand, while collecting insightful information in
each geographical market appropriately.
- Preliminary packaging is now being secured and designs are
completed for each jurisdiction. Please visit the beta version of
the Cannabis Science Patient Access Center (PAC)
http://pac.cannabisscience.com for product release information,
patient usage tracking, share your usage and support stories with
others worldwide, and valuable industry updates.
Cannabis Science will be announcing shortly where products are
available for purchase in each jurisdiction; initial cannabis
formulations will be focused on:
- Topical formulations for cancers
- Ingestible formulations for cancers, HIV/AIDS and other
indications
- Varied formulations for neurological disorders and other
indications depending on delivery methodology required
- Ingestible and topical formulations for chemotherapy side
effects, chronic pain, muscle problems, sleeping disorders, nausea,
ADHD, rheumatism, arthritis, infections, diabetes, manic
depression, fibromyalgia and other issues
- Topical formulations for rheumatism, fibromyalgia, arthritis,
eczema, sporting injuries, radiotherapy wounds, muscle and neck
pain, radiotherapy wounds, rheumatism, open wounds and sensitive
and irritated skin, various skin complaints, and wounds
About Cannabis Science, Inc.
Cannabis Science, Inc.,
takes advantage of its unique understanding of metabolic processes
to provide novel treatment approaches to a number of illnesses for
which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of
years, and currently, there are a growing number of peer-reviewed
scientific publications that document the underlying biochemical
pathways that cannabinoids modulate. The Company works with leading
experts in drug development, medicinal characterization, and
clinical research to develop, produce, and commercialize novel
therapeutic approaches for the treatment for illnesses caused by
infections as well as for age-related illness. Our initial focus is
on skin cancers and neurological conditions.
Forward-Looking Statements
This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing words such as "anticipate," "seek,"
intend," "believe," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Some or all of the events or results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development
of cannabis-based drugs. Cannabis Science, Inc., does not undertake
any duty nor does it intend to update the results of these
forward-looking statements.
Cannabis Science, Inc.
Raymond C. Dabney, Director,
President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
Chad S. Johnson, Esq., Director,
COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Photo - http://photos.prnewswire.com/prnh/20150116/169652
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cannabis-science-inc-cbis-gets-set-to-release-its-8-initial-cannabis-based-products-produced-and-distributed-in-california-spain-and-the-netherlands-for-self-medicating-patient-usage-for-critical-ailments-and-pre-clinical-st-300021763.html
SOURCE Cannabis Science, Inc.